Nanomedicine Presents Unique Challenges to IRBs

Executive Briefing Series
Nanomedicine is an exciting new field that offers great promise, but much about this cutting-edge technology is unknown, which argues for a precautionary approach by institutional review boards (IRB) and researchers to protect all parties involved in nanomedicine trials, a National Institutes of Health- (NIH) funded panel says.

To View This Article:


Buy This Article Now

Add this article to your cart for $40.00